Invitae (NVTA) Stock Analysis

What Invitae does

Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.

Key metrics

ETFs linked to NVTA

Broad-market and Healthcare sector ETFs an investor holding Invitae is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NVTA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Invitae?

Invitae trades under the ticker NVTA on NYSE.

Which exchange is NVTA listed on?

NVTA is listed on NYSE.

What sector does Invitae operate in?

Invitae is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze NVTA in a portfolio?

PortView shows NVTA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.